These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25180876)

  • 1. Atomoxetine for attention deficits following traumatic brain injury: results from a randomized controlled trial.
    Ripley DL; Morey CE; Gerber D; Harrison-Felix C; Brenner LA; Pretz CR; Cusick C; Wesnes K
    Brain Inj; 2014; 28(12):1514-22. PubMed ID: 25180876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
    Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
    J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury.
    Reid WM; Hamm RJ
    J Neurotrauma; 2008 Mar; 25(3):248-56. PubMed ID: 18352838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atomoxetine on executive function impairments in adults with ADHD.
    Brown TE; Holdnack J; Saylor K; Adler L; Spencer T; Williams DW; Padival AK; Schuh K; Trzepacz PT; Kelsey D
    J Atten Disord; 2011 Feb; 15(2):130-8. PubMed ID: 20026871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
    Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
    J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.
    de Jong CG; Van De Voorde S; Roeyers H; Raymaekers R; Allen AJ; Knijff S; Verhelst H; Temmink AH; Smit LM; Rodriques-Pereira R; Vandenberghe D; van Welsen I; ter Schuren L; Al-Hakim M; Amin A; Vlasveld L; Oosterlaan J; Sergeant JA
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):699-707. PubMed ID: 20035588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Traumatic brain injury-related attention deficits: treatment outcomes with lisdexamfetamine dimesylate (Vyvanse).
    Tramontana MG; Cowan RL; Zald D; Prokop JW; Guillamondegui O
    Brain Inj; 2014; 28(11):1461-72. PubMed ID: 24988121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
    Gau SS; Shang CY
    Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
    Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
    J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
    Young JL; Sarkis E; Qiao M; Wietecha L
    Clin Neuropharmacol; 2011; 34(2):51-60. PubMed ID: 21406998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
    Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
    Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.